Search clinical trials for: paclitaxel poliglumex

Total 4030 results

Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Fudan University

Unknown

Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Advanced Pancreatic Cancer

China
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Triple Negative Breast Cancer | Nab-paclitaxel

China
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
Shandong Branden Med.Device Co.,Ltd
Fudan University

Unknown

Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter

In-stent Restenosis

China
Laval University
Boston Scientific Corporation

Completed

Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial (VELETI)

Coronary Artery Bypass Grafting

Canada
Angiotech Pharmaceuticals

Terminated

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

Kidney Diseases | ESRD

United States
Catholic University of the Sacred Heart

Unknown

Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent (IN-PACT CORO)

Coronary Artery Disease

Italy
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
Cordis Corporation
Conor Medsystems

Completed

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

Coronary Disease

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
Samsung Medical Center

Terminated

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Caicun Zhou

Unknown

Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Esophageal Neoplasms

China
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
Montefiore Medical Center

Completed

A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States
Mateon Therapeutics

Withdrawn

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (FACT2)

Anaplastic Thyroid Cancer
Centro Nacional de Investigaciones Oncologicas...
M.D. Anderson Cancer Center; Hospital Universitari de Bellvitge; Grupo Espanol... and other collaborators

Completed

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Breast Cancer

Spain
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Trishula Therapeutics, Inc.
AbbVie

Recruiting

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Pancreatic Cancer

United States, Korea, Republic of
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Fudan University
Shanxi Province Cancer Hospital; Jiangxi Provincial Cancer Hospital; Jiangsu... and other collaborators

Completed

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Stage III Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Lung Cancer

United States
Asan Medical Center
AstraZeneca

Completed

Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer (PRIDE)

Non Small Cell Lung Cancer

Korea, Republic of
NYU Langone Health
Novartis

Terminated

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Ovarian Cancer

United States
Eisai Inc.

Completed

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Spain, United States, Canada, Austria, France, Germany
National Cancer Institute, Naples

Active, not recruiting

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer (MITO-7)

Ovarian Cancer

Italy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma

China
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Guangdong Provincial People's Hospital

Unknown

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Breast Cancer

China
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Cervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant Chemoimmunotherapy

China
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Grupo Español de Tratamiento de Tumores de Cabeza...
Bristol-Myers Squibb; Apices Soluciones S.L.

Active, not recruiting

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX)

Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer Stage IV

Spain
Accenture

Completed

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

Australia, Russian Federation, United Kingdom
Bayer

Terminated

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

China, Taiwan, Singapore, Thailand, Korea, Republic of, India
Genoss Co., Ltd.

Active, not recruiting

Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Chinese Patients With Coronary ISR

Coronary Artery Disease

China
Bayer

Terminated

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung

Belgium, Italy, Spain, Hong Kong, United States, Germany, United Kingdom, Chile, Taiwan, Australia, Canada, Argentina, Puerto Rico, France, Poland, Russian Federation, Sweden, Hungary, Netherlands, Brazil, Korea, Republic of
Mateon Therapeutics

Completed

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Cancer | Tumor

United States

Search clinical trials for: paclitaxel poliglumex

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations